Lymphoma, Extranodal NK-T-Cell - 15 Studies Found

Completed : Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL
: Lymphoma, Extranodal NK-T-Cell
: 2014-03-02
:
  • Drug: GELOX gemcitabine ᦂ
Not yet recruiting : 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
: Lymphoma, Extranodal NK-T-Cell
: 2017-02-09
: Device: 18F-FDG PET/ CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients
Not yet recruiting : Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma
: Lymphoma, Extranodal NK-T-Cell
: 2017-02-09
: Device: 18F-FDG PET/CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients
Terminated : P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
: Lymphoma, Extranodal NK-T-Cell
: 2015-08-24
:
  • Drug: gemcitabine gemcitabine

Completed : GLIDE Regiment Followed by ASCT for Aggressive NK/T Cell Lymphoma
: Lymphoma, Extranodal NK-T-Cell
: 2017-05-02
: Drug: GLIDE The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8
Not yet recruiting : Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation
:
  • Lymphoma, Extranodal NK-T-Cell
  • EBV

: 2016-08-20
:
  • Drug: Chidamide BIW Chidamide

Completed : Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
:
  • Lymphoma, Extranodal NK-T-Cell
  • EBV

: 2013-09-13
: Biological: CMD-003 Autologous EBV-specific T-cells
Active, not recruiting : Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
:
  • Lymphoma, T-Cell
  • Lymphoma, Extranodal NK-T-Cell

: 2003-09-17
:
  • Biological: Alemtuzumab (Campath)

Completed : VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)
: Extranodal NK-T-Cell Lymphoma
: 2015-09-06
:
  • Drug: Etoposide Subjects will

Completed : Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients
: Extranodal NK-T-Cell Lymphoma, Nasal Type
: 2017-03-09
: Combination Product: L-Asparaginase or or Pegaspargase containing chemotherapy Patients receive at least
Next >>>